4512-0106 HIV/AIDS Drug Program Manufacturer Rebates Retained Revenue

For the department of public health, which may expend not more than $15,162,386 for the HIV Drug Assistance Program, or HDAP, from revenues received from pharmaceutical manufacturers participating in the section 340B rebate program of the Public Health Service Act, as codified in 42 U.S.C. section 256b, administered by the Health Resources and Services Administration and the Office of Pharmacy Affairs; provided, that such services shall include activities that would be eligible for coverage through the Ryan White Comprehensive AIDS Resources Emergency Act, Public Law 101--381, with priority given to the human immunodeficiency virus and acquired immune deficiency syndrome drug assistance program; provided further, that any excess rebate revenue collected beyond the ceiling of this appropriation shall be deposited in the General Fund; provided further, that services in an amount equivalent to the amount deposited in the General Fund shall be funded through item 4512--0103; and provided further, that the department may make expenditures from the start of each fiscal year from this item in anticipation of receipt of rebate revenues from pharmaceutical manufacturers